Abstract
Bullous pemphigoid (BP) is an acquired, nonscarring, subepidermal blistering disease, usually occurring in the elderly, but may rarely affect children and younger adults.
BP is considered the most common autoimmune blistering disease. The target antigens are the BP antigens with molecular weights of 230 and 180 kDa, BPAG1 and BPAG2, respectively. Urticarial or eczematous lesions are common prodromal eruptions in BP, by weeks or months. In some cases, bullae may not become clinically apparent. Subsequently, large tense blisters arise with a base of normal or erythematous skin.
The aim of treatment is to suppress the clinical signs and symptoms of BP in order to improve the quality of life of BP patients. The severity of disease, age of patient, and presence of underlying disease must be considered in determining therapeutic agents and doses.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Persson MSM, et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study. Br J Dermatol. 2021;184:68–77. https://doi.org/10.1111/bjd.19022. Epub 2020 Apr 27.
Silverii GA, et al. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine. 2020;69:504–7. https://doi.org/10.1007/s12020-020-02272-x. Epub 2020 Mar 31.
Hammers CM, Stanley JR. Recent advances in understanding pemphigus and bullous pemphigoid. J Invest Dermatol. 2020;140:733–41. https://doi.org/10.1016/j.jid.2019.11.005.
Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-induced pemphigoid. Acta Derm Venereol. 2020;100:adv00224. https://doi.org/10.2340/00015555-3457.
Ben-Shoshan D, et al. The future of bullous pemphigoid (BP): new and promising drugs may revolutionize treatment course for BP patients. J Cutan Med Surg. 2020;24:191–2. https://doi.org/10.1177/1203475419888867. PMID: 32208024.
Geller S. Interleukin 4 and interleukin 13 inhibition: a promising therapeutic approach in bullous pemphigoid. J Am Acad Dermatol. 2020;83:37–8. https://doi.org/10.1016/j.jaad.2020.03.017.
Du-Thanh A, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol. 2011;165:1337–43.
Hideyuki U, et al. What’s new in bullous pemphigoid. J Dermatol. 2010;37:194–204.
Orvis AK, et al. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60(2):183–99.
Neff A, et al. Treatment strategies in mucous membrane pemphigoid. Ther Clin Risk Manag. 2008;4:617–26.
Schmidt E, et al. Serum levels of autoantibodies to BP 180 correlates with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136:174–8.
Tee S, et al. Prevention of glucocorticoidinduced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebocontrolled study. Arch Dermatol. 2012;148:307–14.
Venning VA, et al. British Association of Dermatologists’ guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167:1200–14.
Yancey KB, Egan CA. Pemphigoid. Clinical, histology, immunopathology, and therapeutic considerations. JAMA. 2000;284(3):350–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Stavropoulos, P.G., Larios, G. (2023). Bullous Pemphigoid. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D'Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Cham. https://doi.org/10.1007/978-3-031-15130-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-031-15130-9_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-15129-3
Online ISBN: 978-3-031-15130-9
eBook Packages: MedicineMedicine (R0)